Conversely, BAG3 (rs2234962-C) was not associated with CCM risk in the low-risk group but was associated with a 26% reduction in the high-risk group, where higher doses of cardiotoxic therapies might have slightly modified the SNV’s association. Here, BAG3 is linked to cerebral cavernous malformation.